BIOLIGHT LIFE SCIENCES LTD. Inactive Instrument
BioLight Life Sciences Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
BOLT
IL0010952237
Advanced Medical Equipment & Technology
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 63T 17.05T 14.23L | Sales 2023 | 1L 31.93T 26.65L | Capitalization | 2.41Cr 65.28L 54Cr |
|---|---|---|---|---|---|
| Net income 2022 | -70L -18.94L -16Cr | Net income 2023 | -2.6Cr -70.36L -59Cr | EV / Sales 2022 | 207 x |
| Net cash position 2022 | 1.71Cr 46.27L 39Cr | Net cash position 2023 | 85.52L 23.14L 19Cr | EV / Sales 2023 | 132 x |
| P/E ratio 2022 |
-3.85
x | P/E ratio 2023 |
-0.93
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 43.16% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 01/20/01 | |
Yifftach Biel
DFI | Director of Finance/CFO | 48 | 01/15/01 |
Ron Neumann
CTO | Chief Tech/Sci/R&D Officer | 69 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Israel Makov
CHM | Chairman | 85 | 21/11/21 |
Kobi Faigenbaum
BRD | Director/Board Member | 71 | 11/17/11 |
Alla Felder
BRD | Director/Board Member | 50 | 25/20/25 |
Biolight Life Sciences Ltd, formerly Bio Light Israeli Life Sciences Investments Ltd, is an Israel-based company engaged, through its subsidiaries, in various fields of research and development of pharmaceuticals and medical products and devices. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The Company provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.
| 1st Jan change | Capi. | |
|---|---|---|
| +12.23% | 23TCr | |
| +10.94% | 19TCr | |
| +13.05% | 14TCr | |
| +25.51% | 11TCr | |
| +0.80% | 6.36TCr | |
| +5.62% | 5.13TCr | |
| +12.59% | 5.1TCr | |
| +8.21% | 4.33TCr | |
| +4.76% | 3.7TCr |
